Jeffrey S. Farrow
Net Worth

Last updated:

What is Jeffrey S. Farrow net worth?

The estimated net worth of Mr. Jeffrey S. Farrow is at least $8,922,764 as of 27 Sep 2022. He owns shares worth $211,360 as insider, has earned $3,156,924 from insider trading and has received compensation worth at least $5,554,480 in Global Blood Therapeutics, Inc..

What is the salary of Jeffrey S. Farrow?

Mr. Jeffrey S. Farrow salary is $694,310 per year as Chief Financial Officer & Principal Accounting Officer in Global Blood Therapeutics, Inc..

How old is Jeffrey S. Farrow?

Mr. Jeffrey S. Farrow is 63 years old, born in 1962.

What stocks does Jeffrey S. Farrow currently own?

As insider, Mr. Jeffrey S. Farrow owns shares in one company:

Company Title Shares Price per share Total value
Global Blood Therapeutics, Inc. (GBT) Chief Financial Officer & Principal Accounting Officer 3,086 $68.49 $211,360

What does Global Blood Therapeutics, Inc. do?

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

GBT logo
GBT
Global Blood Therapeutics, Inc.
$68.49

Jeffrey S. Farrow insider trading

Global Blood Therapeutics, Inc.

Mr. Jeffrey S. Farrow has made 3 insider trades between 2017-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 31,441 units of GBT stock on 1 Sep 2022. As of 27 Sep 2022 he still owns at least 3,086 units of GBT stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 23,653 $16.4 $387,909
Option
Stock Option (Right to Buy) 23,653 $16.4 $387,909
Option
Common Stock 2,763 N/A N/A
Option
Restricted Stock Units 2,208 N/A N/A
Sale
Common Stock 31,441 $68 $2,137,988
Option
Restricted Stock Units 2,763 N/A N/A
Option
Common Stock 2,208 N/A N/A
Option
Common Stock 6,145 N/A N/A
Option
Restricted Stock Units 3,125 N/A N/A
Option
Restricted Stock Units 3,020 N/A N/A
Option
Restricted Stock Units 2,763 N/A N/A
Option
Common Stock 2,763 N/A N/A
Option
Common Stock 9,020 N/A N/A
Option
Restricted Stock Units 2,875 N/A N/A
Option
Restricted Stock Units 3,125 N/A N/A
Option
Restricted Stock Units 3,020 N/A N/A
Option
Restricted Stock Units 2,762 N/A N/A
Option
Common Stock 2,762 N/A N/A
Option
Common Stock 9,020 N/A N/A
Option
Restricted Stock Units 9,020 N/A N/A
Option
Restricted Stock Units 12,083 N/A N/A
Option
Common Stock 12,083 N/A N/A
Option
Common Stock 12,082 N/A N/A
Option
Restricted Stock Units 9,062 N/A N/A
Option
Restricted Stock Units 12,082 N/A N/A
Sale
Common Stock 15,208 N/A N/A
Sale
Common Stock 15,208 $67 $1,018,936
Option
Restricted Stock Units 9,063 $21.94 $198,842
Option
Common Stock 9,063 N/A N/A
Option
Restricted Stock Units 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Restricted Stock Units 9,062 N/A N/A
Option
Common Stock 9,062 N/A N/A
Option
Restricted Stock Units 9,062 N/A N/A
Option
Restricted Stock Units 2,000 N/A N/A
Option
Common Stock 2,000 N/A N/A
Option
Common Stock 5,938 N/A N/A
Option
Restricted Stock Units 5,938 N/A N/A
Option
Common Stock 3,048 $16.4 $49,987
Option
Stock Option (Right to Buy) 3,048 $16.4 $49,987
Option
Restricted Stock Units 5,937 N/A N/A
Option
Common Stock 5,937 N/A N/A
Option
Restricted Stock Units 5,937 N/A N/A
Option
Common Stock 2,000 N/A N/A
Option
Restricted Stock Units 2,000 N/A N/A
Option
Restricted Stock Units 3,063 N/A N/A
Option
Common Stock 3,063 N/A N/A
Option
Restricted Stock Units 2,000 $59.6 $119,200
Option
Common Stock 2,000 $59.6 $119,200
Option
Restricted Stock Units 2,000 N/A N/A
Option
Common Stock 2,000 N/A N/A
Option
Common Stock 2,000 N/A N/A
Option
Restricted Stock Units 2,000 N/A N/A
Option
Common Stock 3,062 N/A N/A
Option
Restricted Stock Units 3,062 N/A N/A

Global Blood Therapeutics key executives

Global Blood Therapeutics, Inc. executives and other stock owners filed with the SEC: